Compare Illumina, Inc. (ILMN) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Ross Stores, Inc. — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Ross Stores, Inc. trades at $252.25 (market cap $81.74B). The key difference: Ross Stores, Inc. is far larger — about 2.8× Illumina, Inc.'s market cap, and Ross Stores, Inc. pays a 0.7% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | ROST | |
|---|---|---|
Market Cap | $28.96B | $81.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $205.10 | $255.23 |
52-Week Low | $91.00 | $144.67 |
Enterprise Value | $30.32B | $82.34B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Ross Stores (ROST) trades at $255.23, up 0.36% on the day, near its consensus price target of $259. The stock shows strong momentum with a bullish technical signal and consistent earnings beats, including Q1 2026 EPS of $2.02 versus $1.73 expected. Revenue growth accelerated to $21.13B in 2025, with net income margin improving to 9.74%. Recent expansion includes 47 new stores opened in June-July 2026, supporting future growth.
Outlook remains positive given robust fundamentals and analyst optimism, but valuation multiples like P/E of 35.65 suggest premium pricing. Key risks include consumer spending sensitivity and competitive pressures in discount retail. The stock offers growth potential with disciplined execution, though investors should weigh high valuation against earnings sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
